ADVEXIN
information and resources from the National Cancer Institute
ADVEXIN
(Other name for: Ad5CMV-p53 gene)AE-941
A multifunctional antiangiogenic agent derived from shark cartilage with potential antineoplastic activity. Neovastat competitively inhibits the binding of pro-angiogenic vascular endothelial growth factor (VEGF) to its cell receptor, thereby inhibiting endothelial cell proliferation. This agent also inhibits matrix metalloproteinases (MMPs), stimulates tissue plasminogen activator (tPA), and activates caspase-mediated apoptotic pathways in endothelial cells.ADVEXIN
(Other name for: Ad5CMV-p53 gene)
|
|
|
|
news articles
Advexin® Promising for Inoperable, Refractory Esophageal Cancer Mar 20, 2006
Cancer Consultants (press release), According to a press release by Introgen Therapeutics, Inc., the vaccine Advexin® appears promising as single-agent therapy in patients with inoperable ...
(PRN) Recent FDA Action Validates ADVEXIN(R) Registration Strategy ... Mar 3, 2006
Houston Chronicle, ...and neck cancer. This affirms the approval approach taken by Introgen in its ADVEXIN(R) global registration program. There are an ...
Introgen Shows Advexin Trial Results Mar 16, 2006
Houston Chronicle, ...said Thursday that an early- to mid-stage clinical trial showed that its Advexin cancer treatment stabilized a form of the disease in nine out of 10 patients. ...
Introgen reports Advexin trial results Mar 16, 2006
BusinessWeek ...said Thursday that an early- to mid-stage clinical trial showed that Advexin cancer treatment its stabilized the disease in nine out of 10 patients. ...
(PRN) Phase I/II Clinical Data Demonstrate Safety and Antitumor ... Mar 16, 2006
Houston Chronicle, ...(Nasdaq: INGN) today announced the publication of positive data from a Phase I/II clinical trial of ADVEXIN(R) in advanced esophageal cancer patients. ...
Phase 1/2 Clinical Data Demonstrate Safety and Antitumor Activity ... Mar 16, 2006
DG News ...today announced the publication of positive data from a phase 1/2 clinical trial of Advexin(R) in advanced esophageal cancer patients. ...
Introgen Therapeutics Says Data From Phase I/II Clinical Trial ... Mar 16, 2006
Trading Markets, ...(RTTNews) - Introgen Therapeutics Inc. (INGN | charts | news | Powerrating) on Thursday said data from a Phase I/II clinical trial of ADVEXIN in advanced ...
New Ideas Fuel Next Generation Gene Therapy Research Mar 7, 2006
eMaxHealth.com, Introgen conducted phase II studies on the therapy, which it calls Advexin, and found that lung tumors shrank in over half of the patients who used it when ...
(PRN) - Apartment Investment and Management Company to Participate ... Mar 3, 2006
Bolsamania.com, ...[+]. (PRN) - Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Encouraged By Approval of Erbitux(R) for Head and Neck Cancer ... [+. ...
(PRN) - DiagnoCure announces fiscal 2006 first quarter results ... ... Mar 16, 2006
Bolsamania.com, ...[+]. (PRN) - Phase I/II Clinical Data Demonstrate Safety and Antitumor Activity of Introgen's ADVEXIN(R) in Patients With Advanced Esophageal Cancer ... [+. ...
Encouraging Results of Introgen's ADVEXIN Breast Cancer Treatment ... Dec 8, 2005
PR Newswire (press release), ...- ADVEXIN Increases Effects of Neoadjuvant Chemotherapy - AUSTIN, Texas, Dec. 8 /PRNewswire-FirstCall/ -- Introgen Therapeutics, Inc. ...
Encouraging Results of Introgen's ADVEXIN Breast Cancer Treatment ... Dec 8, 2005
PharmaLive.com (press release), ...today reported an update of data from its Phase 2 trial evaluating ADVEXIN(R) combined with neoadjuvant chemotherapy and surgery in women with locally advanced ...
Advexin Reduces Breast Cancer Tumor Size Dec 5, 2005
CancerWise Breast cancer tumor size decreased an average of nearly 80% when patients in a new study took the gene-based drug Advexin® with traditional chemotherapy drugs ...
Encouraging Results of Introgen's ADVEXIN Breast Cancer Treatment ... Dec 8, 2005
Yahoo! News (press release) ...(Nasdaq: INGN - News) today reported an update of data from its Phase 2 trial evaluating ADVEXIN® combined with neoadjuvant chemotherapy and surgery in women ...
|
|
